Skip to main content

Fiscal Wizard · Single-issue tearsheet

KROS / Jun 22, 2026 Run #7628

KROS

Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Composite verdict

D 44.4 / 100
Bearish setup · Reversal 13 drivers · 4 gates blocking
  • Vortex Signal
  • MA Rejection
  • Chaikin Money Flow
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 92nd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 18 signals100% Bear
Momentum Bearish 2Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -96%
Asset value $15.32Earnings power value $49.59Price $10.65

Trading below its asset value ($15.32/share) — deep value, but check for a melting balance sheet.

Fundamentals Strong

88.7 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Days Sales Outstanding 100
Margin of Safety 0
EPS Growth (YoY) 100
PEG 3
Earnings Yield 100
Gross Margin 25

Technicals Bearish

0.1 / 100

Bearish setup leads (Vortex Signal, MA Rejection, Chaikin Money Flow); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Vortex Signal 10
Chaikin Money Flow 14
MA Rejection 14

Risk Gates

4 blocking 3 caution

4 guards active, 22 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for KROS.